The Data-driven Clinical Decision Processes section focuses on the changes and transformations enabled by Big Data that have have direct effects on translational medicine. Superior precision is expected from a more data-intensive and individualized medicine, accelerating scientific discovery and innovation. At the other end, the scientific method needs to adapt to the increased diversity that data presents.
Edited by Enrico Capobianco, this section welcomes multidisciplinary research, and aims to promote scientific interactions and accelerate the establishment of CDSS in the clinical practice.
Read the latest articles in the Data-driven Clinical Decision Processes section
Moon et al, 2021
Scleroderma is an autoimmune disease that causes dermal fibrosis and occurs when collagen accumulates in tissue as a result of persistent inflammation. Th17 cells and pro-inflammatory cytokines play important roles in the pathogenesis of scleroderma. Previous studies have demonstrated metformin, a medication used to treat diabetes, has effective immunoregulatory functions. It suppresses the development of lung fibrosis and inflammatory bowel disease by regulating the Th17–IL-17 axis.
This study aims to investigate the function of metformin in scleroderma. Researchers demonstrate that metformin ameliorates scleroderma in a mouse model by inhibiting Th17 cells via the regulation of mTOR-STAT3 signaling.
Wang et al, 2021
Acute respiratory distress syndrome (ARDS) remains the leading cause of mortality in critically ill patients. The emergence of the coronavirus disease 2019 has become a global issue with raising dire concerns, and patients with severe Covid-19 may progress toward ARDS. Mesenchymal stem cells (MSC) are multipotent adult stem cells derived from various tissues and organs. MSC-based therapies are widely used for the treatment of several diseases in pre-clinical models and under investigation in many clinical trials. While accumulating evidence suggests that mesenchymal stem cell infusion can ameliorate ARDS, the underlying mechanisms of MSCs need to be discussed.
In this review, Wang et al summarize the therapeutic mechanisms of MSCs in ARDS, analyze the most recent animal experiments and Covid-19 clinical trial results, discuss the adverse effects and prospects in the recent studies, and highlight the potential roles of MSC therapy for Covid-19 patients with ARDS.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreGet to know the Editors behind Journal of Translational Medicine!
Check out last month's top 20 most discussed articles from Journal of Translational Medicine!
nadia_buravleva / stock.adobe.com
Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020).
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Giuseppe Intini, this new section aims to foster new discoveries in the field of Craniofacial and Dental Medicine. It is interested in interested in research that investigates innovative approaches in all craniofacial and dental specialties, including oral medicine and oral pathology.
Translational Craniofacial and Dental Medicine will consider studies regarding therapeutic approaches for treatment of diseases and for tissue regeneration, biomaterials for restorative prosthesis and implantology, diagnostic tools, imaging, and large data analysis. Translational genomics and precision medicine studies that identify novel prognostic markers, tailored interventions, and prophylactic approaches are also welcome.
Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity.
Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.
Led by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.
Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.
Led by Section Editor Souhaila Al Khodor, this new section aims to fill the gap between basic research, translational medicine, and high-throughput data analysis for the human microbiome by providing innovative and novel scientific ideas.
Translational Metagenomics encompasses studies about the development and application of metagenomics, metatranscriptomics, microbial metabolomics or novel bioinformatics tools used to improve our knowledge on the microbiome. The section is especially interested in studies that go beyond description of the microbial composition and include experimental models used to support the proposed role of the microbiome in human health and diseases.
Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.
Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
Speed
60 days to first decision for reviewed manuscripts only
31 days to first decision for all manuscripts
115 days from submission to acceptance
13 days from acceptance to publication
Citation Impact
5.531 - 2-year Impact Factor
5.760 - 5-year Impact Factor
1.244 - Source Normalized Impact per Paper (SNIP)
1.576 - SCImago Journal Rank (SJR)
Usage
2,701,735 Downloads
3,471 mentions